Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.

NCT01571635 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01571635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01571635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Terminated
Start date
October 10, 2012
Completion date
May 24, 2022
Enrollment
46 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

beta thalassemia intermedia, beta thalassemia major